From their presentation:If someone could save me from scanning the length of this thread, when is the Phase 2 trial presumed to begin?
Expect to initiate Phase 2 trial in 1Q21 with results mid-2022.
From their presentation:If someone could save me from scanning the length of this thread, when is the Phase 2 trial presumed to begin?
I don't see anything about it on clinical trials page. I hope it is still going on as planned.From their presentation:
Expect to initiate Phase 2 trial in 1Q21 with results mid-2022.
Top line results here:Where are the results of OTO-313?
Interesting that for Phase 2, they aren't upping the dose, only changing the criteria to exclude hearing loss and increase minimum TFI. That should beat the 43% responder rate reported here.
It's not a regenerative drug so no. The main con would be that so far, it has only been tested on acute cases (under 6 months). It is unknown if it works chronically but the company intends to use a longer time period (unknown how long) for the next trial.@FGG, what are the cons of OTO-313? Does it deplete support cells?
Why wouldn't it work for chronic tinnitus?It's not a regenerative drug so no. The main con would be that so far, it has only been tested on acute cases (under 6 months). It is unknown if it works chronically but the company intends to use a longer time period (unknown how long) for the next trial.
Some people speculate whether or not there is a window for cochlear NMDA receptor antagonists to work because it has a lot to do with initial cochlear response to inflammation but there is also some evidence at least for some people it may work chronically too. So it's really unknown atm. Something the next trial may address.Why wouldn't it work for chronic tinnitus?
If only we knew the mechanism behind setbacks. I wonder how Dr. Fuchs and his animal model are coming along.Some people speculate whether or not there is a window for cochlear NMDA receptor antagonists to work because it has a lot to do with initial cochlear response to inflammation but there is also some evidence at least for some people it may work chronically too. So it's really unknown atm. Something the next trial may address.
I was told one year.It's not a regenerative drug so no. The main con would be that so far, it has only been tested on acute cases (under 6 months). It is unknown if it works chronically but the company intends to use a longer time period (unknown how long) for the next trial.
Great news! In my opinion a 12 month onset window can basically be counted as chronic, can it not? My chronic increases usually have "settled" to a steady level after about 6 months. At 12 months I'd say it's definitely "stuck".
That only makes you think that it will be a failure.Interesting that for Phase 2, they aren't upping the dose, only changing the criteria to exclude hearing loss and increase minimum TFI. That should beat the 43% responder rate reported here.
Hopefully they take notes on the disastrous FX-322 trial and change their methodology accordingly.
Here we go again... you need a minimal TFI level to be selected. Where have we seen this before?Interesting that for Phase 2, they aren't upping the dose, only changing the criteria to exclude hearing loss and increase minimum TFI. That should beat the 43% responder rate reported here.
Here we go again... you need a minimal TFI level to be selected. Where have we seen this before?
This one doesn't even need bad actors. Literally the stress of having high enough TFI to get in could actually inflate TFI at baseline, lol.
So is this dead?Here we go again... you need a minimal TFI level to be selected. Where have we seen this before?
This one doesn't even need bad actors. Literally the stress of having high enough TFI to get in could actually inflate TFI at baseline, lol.
They just announced initiation of Phase 2, and apparently it will be conducted also in Europe:Does anyone know when the OTO-313 Phase 2 clinical trial starts? I can't find it on the ClinicalTrials.gov page.
Thanks.
We never got an update as far as I know...@FGG, didn't @ChrisBoyMonkey have a bad reaction to OTO-313? I thought he was trying to see if he got the placebo or real thing to be sure and I went on sabbatical from here before I learned the outcome... maybe you recall?
At the time I was thinking of doing the first study, then read his reports (if my memory is working correctly). I chickened out for that first trial, hoping things would settle down (insert face palm here).
Thanks